

<b>CMS Manual System</b>	<b>Department of Health &amp; Human Services (DHHS)</b>
<b>Pub 100-03 Medicare National Coverage Determinations</b>	<b>Centers for Medicare &amp; Medicaid Services (CMS)</b>
<b>Transmittal 214</b>	<b>Date: March 6, 2019</b>
	<b>Change Request 10878</b>

**Transmittal 210, dated November 30, 2018, is being rescinded and replaced by Transmittal 214, dated, March 6, 2019 to extend the implementation date 30 days and update the attached diagnosis code list. This instruction is being re-communicated to include attachment that was omitted. The Transmittal number, Date issued and all other information remain the same.**

**SUBJECT: National Coverage Determination (NCD90.2): Next Generation Sequencing (NGS)**

**I. SUMMARY OF CHANGES: CMS IS SENSITIVE TO THE CONCERNS OF ITS STAKEHOLDERS REGARDING THE INTERPRETATION OF THIS POLICY AND WILL WORK WITH THE MACS TO ADJUST THEIR RESPECTIVE CLAIMS PROCESSING SYSTEMS ACCORDINGLY. THANK YOU FOR YOUR PATIENCE AS WE WORK THROUGH THESE OUTSTANDING ISSUES.**

The purpose of this Change Request (CR) is to inform contractors that effective March 16, 2018, the Centers for Medicare & Medicaid Services covers diagnostic laboratory tests using next generation sequencing when performed in a Clinical Laboratory Improvement Amendments- certified laboratory when ordered by a treating physician and when specific requirements are met.

**THIS CHANGE REQUEST (CR) AND PUBLICATION (PUB.) 100-03 MANUAL TRANSMITTAL REFLECTS THE AGENCY'S FINAL DECISION DATED MARCH 16, 2018, REGARDING THE NATIONAL COVERAGE DETERMINATION (NCD) 90.2, ON NEXT GENERATION SEQUENCING (NGS). A SUBSEQUENT CR WILL BE RELEASED AT A LATER DATE THAT CONTAINS A PUB. 100-04 CLAIMS PROCESSING MANUAL UPDATE AND FURTHER, ACCOMPANYING INSTRUCTIONS. UNTIL THAT TIME, THE MEDICARE ADMINISTRATIVE CONTRACTORS (MACS) SHALL BE RESPONSIBLE FOR IMPLEMENTING NCD 90.2.**

This revision to the Medicare National Coverage Determinations Manual is a national coverage determination (NCD). NCDs are binding on Medicare Administrative Contractors (MACs) with the Federal government that review and/or adjudicate claims, determinations, and/or decisions, quality improvement organizations, qualified independent contractors, the Medicare appeals council, and administrative law judges (ALJs) (see 42 CFR section 405.1060(a)(4) (2005)). An NCD that expands coverage is also binding on a Medicare advantage organization. In addition, an ALJ may not review an NCD. (See section 1869(f)(1)(A)(i) of the Social Security Act.)

**EFFECTIVE DATE: March 16, 2018**

*\*Unless otherwise specified, the effective date is the date of service.*

**IMPLEMENTATION DATE: April 8, 2019 - 120 days from issuance of initial CR10878 issued on 11/30/18—A/B MACs**

***Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire***

*table of contents.*

**II. CHANGES IN MANUAL INSTRUCTIONS:** (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-*Only One Per Row.*

<b>R/N/D</b>	<b>CHAPTER / SECTION / SUBSECTION / TITLE</b>
R	1/Table of Contents
N	1/90.2/Next Generation Sequencing (NGS)

**III. FUNDING:**

**For Medicare Administrative Contractors (MACs):**

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

**IV. ATTACHMENTS:**

**Business Requirements  
Manual Instruction**

# Attachment - Business Requirements

Pub. 100-03	Transmittal: 214	Date: March 6, 2019	Change Request: 10878
-------------	------------------	---------------------	-----------------------

**Transmittal 210, dated November 30, 2018, is being rescinded and replaced by Transmittal 214, dated, March 6, 2019 to extend the implementation date 30 days and update the attached diagnosis code list. This instruction is being re-communicated to include attachment that was omitted. The Transmittal number, Date issued and all other information remain the same.**

**SUBJECT: National Coverage Determination (NCD90.2): Next Generation Sequencing (NGS)**

**EFFECTIVE DATE: March 16, 2018**

*\*Unless otherwise specified, the effective date is the date of service.*

**IMPLEMENTATION DATE: April 8, 2019 - 120 days from issuance of initial CR10878 issued on 11/30/18—A/B MACs**

## I. GENERAL INFORMATION

**A. Background:** Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, in vitro companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variation as a laboratory diagnostic test, such as when used as a companion in vitro diagnostic test.

Patients with advanced cancer can have recurrent, relapsed, refractory, metastatic, and/or stages III or IV of cancer. Clinical studies show that genetic variations in a patient's cancer can, in concert with clinical factors, predict how each individual responds to specific treatments.

In application, a report of results of a diagnostic laboratory test using NGS (i.e., information on the cancer's genetic variations) can contribute to predicting a patient's response to a given drug: good, bad, or none at all. Applications of NGS to predict a patient's response to treatment occurs ideally prior to initiation of the drug.

The Centers for Medicare & Medicaid Services (CMS) reviewed the evidence for laboratory diagnostic tests using NGS in patients with cancer, and determined that such tests with analytical and clinical validity, and clinical utility, could also improve health outcomes for Medicare beneficiaries with advanced cancer. Therefore CMS shall cover certain diagnostic laboratory tests using NGS under the conditions specified below.

**B. Policy:** Effective for claims with dates of service on or after March 16, 2018, CMS has determined that the evidence is sufficient to cover diagnostic laboratory tests that use NGS under specified conditions. CMS will cover such testing under the Medicare program for beneficiaries with recurrent, relapsed, refractory, metastatic cancer, or advanced stages III or IV cancer if the beneficiary has either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician, and decided to seek further cancer treatment (e.g., therapeutic chemotherapy). The test must be ordered by the treating physician, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, and have all of the following requirements met:

- Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and,
- an FDA-approved or -cleared indication for use in that patient's cancer; and,
- results provided to the treating physician for management of the patient using a report template to specify treatment options.

Additionally, Medicare Administrative Contractors may determine coverage of other diagnostic laboratory tests using NGS for patients with cancer only when the test is performed in a CLIA-certified laboratory, ordered by the treating physician and the patient has:

- either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and,
- either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and,
- decided to seek further cancer treatment (e.g., therapeutic chemotherapy).

A diagnostic laboratory test using NGS is non-covered when cancer patients do not have the above-noted indications for cancer under either national or local coverage criteria.

## II. BUSINESS REQUIREMENTS TABLE

*"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.*

Number	Requirement	Responsibility								Other
		A/B MAC		D M E M A C	Shared- System Maintainers					
		A	B		H H H	F I S S	M C S	V M S	C W F	
10878.1	Effective for dates of service on or after March 16, 2018, contractors shall cover diagnostic laboratory tests using NGS consistent with the NCD Manual, Publication 100.3, Part 1, Section 90.2.	X	X							
10878.2	Contractors shall refer to Attachment 1 for a list of covered clinical diagnostic laboratory tests using NGS and respective allowed ICD-10 diagnosis codes for the listed effective dates. Contractors shall refer to Attachment 1 for a list of covered tests using NGS and respective allowed ICD-10 diagnosis codes for effective date listed. Contractors shall be notified of updates to Attachment 1 through a Technical Direction Letter.  NOTE: While the attached ICD-10 diagnosis code lists include a number of ‘unspecified’ codes, CMS clarifies that it continues to advocate for and encourage that claims be prepared with codes that provide the highest level of specificity when they are available.	X	X							
10878.2.1	Contractors shall use CPT code 81455 for covered clinical diagnostic laboratory test FoundationOne CDx and this test’s respective allowed ICD-10 diagnosis codes listed in Attachment 1 for claims with dates of	X	X							CMS

Number	Requirement	Responsibility									
		A/B MAC		H H H	D M E M A C	Shared- System Maintainers				Other	
		A	B			F I S S	M C S	V M S	C W F		
	service between 03/16/2018 and 03/31/2018.										
10878.3	<p>Contractors shall use default CAQH CORE messages where appropriate: RARC N386 with CARC 50, 96, and/or 119. See latest CAQH CORE update. When denying claims associated with the attached NCDs, except where otherwise indicated, A/B MACs shall use:</p> <p>Group Code PR (Patient Responsibility) assigning financial responsibility to the beneficiary (if a claim is received with occurrence code 32, or with occurrence code 32 and a GA modifier, indicating a signed ABN is on file).</p> <p>Group Code CO (Contractual Obligation) assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file). For modifier GZ, use CARC 50 and MSN 8.81 per instructions in CR 7228/TR 2148.</p> <p>NOTE: This replicates the note under the Policy section.</p>	X	X								
10878.4	A/B MACs shall work together collaboratively from a clinical aspect to ensure consistent national editing across jurisdictions.	X	X								
10878.4.1	<p>Contractors shall attend up to four 1-hour calls to discuss feedback regarding implementation of coding for this policy and how to ensure consistent national editing across MACs.</p> <p>NOTE: CMS shall schedule the calls at a later date.</p>	X	X								
10878.4.2	<p>Contractors shall be responsible for taking meeting notes on a rotating basis and submit notes to ECHIMP within 3 business days of meeting.</p> <p>Contractors shall appoint appropriate points-of-contact for staffing the meetings within seven business days from the date of this CR and email the name(s) to:Katherine.Szarama@cms.hhs.gov</p>	X	X								

Number	Requirement	Responsibility									
		A/B MAC		H H H	D M E M A C	Shared-System Maintainers				Other	
		A	B			F I S S	M C S	V M S	C W F		
10878.5	Contractors shall provide consensus recommendations to CMS in a final report uploaded into ECHIMP, under the Post Issued tab, Analysis Call Documents sub-tab, no later than 30 business days following the final meeting.	X	X								
10878.6	Contractors shall ensure that no co-insurance or deductible is applied for covered tests using NGS when paid under the Clinical Laboratory Fee Schedule (CLFS).		X								
10878.7	A/B MACs shall implement local edits in each respective jurisdiction until such time as CMS may determine shared edits to be appropriate, which will be relayed via a subsequent CR.	X	X								

**III. PROVIDER EDUCATION TABLE**

Number	Requirement	Responsibility									
		A/B MAC		H H H	D M E M A C	Shared-System Maintainers				Other	
		A	B			F I S S	M C S	V M S	C W F		
10878.8	MLN Article: CMS will make available an MLN Matters provider education article that will be marketed through the MLN Connects weekly newsletter shortly after the CR is released. MACs shall follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1, instructions for distributing MLN Connects information to providers, posting the article or a direct link to the article on your website, and including the article or a direct link to the article in your bulletin or newsletter. You may supplement MLN Matters articles with localized information benefiting your provider community in billing and administering the Medicare program correctly. Subscribe to the “MLN Matters” listserv to get article release notifications, or review them in the MLN Connects weekly newsletter.	X	X								

**IV. SUPPORTING INFORMATION**

**Section A: Recommendations and supporting information associated with listed requirements: N/A**

*"Should" denotes a recommendation.*

<b>X-Ref Requirement Number</b>	<b>Recommendations or other supporting information:</b>
---------------------------------	---

**Section B: All other recommendations and supporting information:** N/A

## **V. CONTACTS**

**Pre-Implementation Contact(s):** Wanda Belle, 410-786-7491 or wanda.belle@cms.hhs.gov (Coverage and Analysis) , Katherine Szarama, 410-786-2840 or Katherine.Szarama@cms.hhs.gov (Coverage and Analysis) , Patricia Brocato-Simons, 410-786-0261 or Patricia.Brocatosimons@cms.hhs.gov (Coverage and Analysis)

**Post-Implementation Contact(s):** Contact your Contracting Officer's Representative (COR).

## **VI. FUNDING**

### **Section A: For Medicare Administrative Contractors (MACs):**

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

**ATTACHMENTS: 1**

# **Medicare National Coverage Determinations Manual Chapter 1, Part 2 (Sections 90-160.26)**

*Table of Contents*  
*(Rev.214, Issued: 03-06-  
19)*

*90.2 Next-Generation Sequencing for Patients with Advanced Cancer*



## **90.2 Next Generation Sequencing (NGS) for Patients with Advanced Cancer**

*(Rev.214, Issued: 03-06-19, Effective: 03-16-18, Implementation: 04-18-19)*

### **A. General**

*Clinical laboratory diagnostic tests can include tests that, for example, predict the risk associated with one or more genetic variations. In addition, in vitro companion diagnostic laboratory tests provide a report of test results of genetic variations and are essential for the safe and effective use of a corresponding therapeutic product. Next Generation Sequencing (NGS) is one technique that can measure one or more genetic variations as a laboratory diagnostic test, such as when used as a companion in vitro diagnostic test.*

*Patients with cancer can have recurrent, relapsed, refractory, metastatic, and/or advanced stages III or IV of cancer. Clinical studies show that genetic variations in a patient's cancer can, in concert with clinical factors, predict how each individual responds to specific treatments.*

*In application, a report of results of a diagnostic laboratory test using NGS (i.e., information on the cancer's genetic variations) can contribute to predicting a patient's response to a given drug: good, bad, or none at all. Applications of NGS to predict a patient's response to treatment occurs ideally prior to initiation of such treatment.*

### **B. Nationally Covered Indications**

*Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician, and when all of the following requirements are met:*

- 1. Patient has:*
  - either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and,*
  - either not been previously tested using the same NGS test for the same primary diagnosis of cancer, or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and,*
  - decided to seek further cancer treatment (e.g., therapeutic chemotherapy).*
- 2. The diagnostic laboratory test using NGS must have:*
  - Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and,*
  - an FDA-approved or -cleared indication for use in that patient's cancer; and,*
  - results provided to the treating physician for management of the patient using a report template to specify treatment options.*

### **C. Nationally Non-Covered**

Effective for services performed on or after March 16, 2018, NGS as a diagnostic laboratory test for patients with cancer are non-covered if the cancer patient does not meet the criteria noted in section B.1. above.

## **D. Other**

1. *Effective for services performed on or after March 16, 2018, Medicare Administrative Contractors (MACs) may determine coverage of other NGS as a diagnostic laboratory test for patients with cancer only when the test is performed in a CLIA-certified laboratory, ordered by a treating physician, and the patient has:*
  - *either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and,*
  - *either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test was performed only when a new primary cancer diagnosis is made by the treating physician; and,*
  - *decided to seek further cancer treatment (e.g., therapeutic chemotherapy).*

*(This NCD last reviewed March 2018.)*

## ICD-10-CM

## ICD-10-CM Code Descriptor

Effective Date: 04/01/2018

C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.2	Malignant neoplasm of external lip, unspecified
C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue
C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C06.2	Malignant neoplasm of retromolar area
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C07	Malignant neoplasm of parotid gland
C08.0	Malignant neoplasm of submandibular gland
C08.1	Malignant neoplasm of sublingual gland
C08.9	Malignant neoplasm of major salivary gland, unspecified
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx

Note that claims for F1CDx test 03/16/2018-03/31/2018 will be recognized with NOC/NOS code 81455 coverable under this policy.

C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13.0	Malignant neoplasm of postcricoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22.0	Liver cell carcinoma
C22.1	Intrahepatic bile duct carcinoma
C22.2	Hepatoblastoma
C22.3	Angiosarcoma of liver
C22.4	Other sarcomas of liver
C22.7	Other specified carcinomas of liver
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C23	Malignant neoplasm of gallbladder
C24.0	Malignant neoplasm of extrahepatic bile duct

C24.1 Malignant neoplasm of ampulla of Vater  
C24.8 Malignant neoplasm of overlapping sites of biliary tract  
C24.9 Malignant neoplasm of biliary tract, unspecified  
C25.0 Malignant neoplasm of head of pancreas  
C25.1 Malignant neoplasm of body of pancreas  
C25.2 Malignant neoplasm of tail of pancreas  
C25.3 Malignant neoplasm of pancreatic duct  
C25.4 Malignant neoplasm of endocrine pancreas  
C25.7 Malignant neoplasm of other parts of pancreas  
C25.8 Malignant neoplasm of overlapping sites of pancreas  
C25.9 Malignant neoplasm of pancreas, unspecified  
C26.0 Malignant neoplasm of intestinal tract, part unspecified  
C26.1 Malignant neoplasm of spleen  
C26.9 Malignant neoplasm of ill-defined sites within the digestive system  
C30.0 Malignant neoplasm of nasal cavity  
C30.1 Malignant neoplasm of middle ear  
C31.0 Malignant neoplasm of maxillary sinus  
C31.1 Malignant neoplasm of ethmoidal sinus  
C31.2 Malignant neoplasm of frontal sinus  
C31.3 Malignant neoplasm of sphenoid sinus  
C31.8 Malignant neoplasm of overlapping sites of accessory sinuses  
C31.9 Malignant neoplasm of accessory sinus, unspecified  
C32.0 Malignant neoplasm of glottis  
C32.1 Malignant neoplasm of supraglottis  
C32.2 Malignant neoplasm of subglottis  
C32.3 Malignant neoplasm of laryngeal cartilage  
C32.8 Malignant neoplasm of overlapping sites of larynx  
C32.9 Malignant neoplasm of larynx, unspecified  
C33 Malignant neoplasm of trachea  
C34.00 Malignant neoplasm of unspecified main bronchus  
C34.01 Malignant neoplasm of right main bronchus  
C34.02 Malignant neoplasm of left main bronchus  
C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung  
C34.11 Malignant neoplasm of upper lobe, right bronchus or lung  
C34.12 Malignant neoplasm of upper lobe, left bronchus or lung  
C34.2 Malignant neoplasm of middle lobe, bronchus or lung  
C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung  
C34.31 Malignant neoplasm of lower lobe, right bronchus or lung  
C34.32 Malignant neoplasm of lower lobe, left bronchus or lung  
C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung  
C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung  
C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung  
C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung  
C34.91 Malignant neoplasm of unspecified part of right bronchus or lung  
C34.92 Malignant neoplasm of unspecified part of left bronchus or lung  
C37 Malignant neoplasm of thymus  
C38.0 Malignant neoplasm of heart  
C38.1 Malignant neoplasm of anterior mediastinum  
C38.2 Malignant neoplasm of posterior mediastinum  
C38.3 Malignant neoplasm of mediastinum, part unspecified  
C38.4 Malignant neoplasm of pleura  
C38.8 Malignant neoplasm of overlapping sites of heart, mediastinum and pleura  
C39.0 Malignant neoplasm of upper respiratory tract, part unspecified  
C39.9 Malignant neoplasm of lower respiratory tract, part unspecified  
C40.00 Malignant neoplasm of scapula and long bones of unspecified upper limb  
C40.01 Malignant neoplasm of scapula and long bones of right upper limb  
C40.02 Malignant neoplasm of scapula and long bones of left upper limb

C40.10	Malignant neoplasm of short bones of unspecified upper limb	
C40.11	Malignant neoplasm of short bones of right upper limb	
C40.12	Malignant neoplasm of short bones of left upper limb	
C40.20	Malignant neoplasm of long bones of unspecified lower limb	
C40.21	Malignant neoplasm of long bones of right lower limb	
C40.22	Malignant neoplasm of long bones of left lower limb	
C40.30	Malignant neoplasm of short bones of unspecified lower limb	
C40.31	Malignant neoplasm of short bones of right lower limb	
C40.32	Malignant neoplasm of short bones of left lower limb	
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	
C41.0	Malignant neoplasm of bones of skull and face	
C41.1	Malignant neoplasm of mandible	
C41.2	Malignant neoplasm of vertebral column	
C41.3	Malignant neoplasm of ribs, sternum and clavicle	
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	
C43.0	Malignant melanoma of lip	
C43.10	Malignant melanoma of unspecified eyelid, including canthus	
C43.11	Malignant melanoma of right eyelid, including canthus	Expired 9/30/2018
C43.111	Malignant melanoma of right upper eyelid, including canthus	Effective 10/1/2018
C43.112	Malignant melanoma of right lower eyelid, including canthus	Effective 10/1/2018
C43.12	Malignant melanoma of left eyelid, including canthus	Expired 9/30/2018
C43.121	Malignant melanoma of left upper eyelid, including canthus	Effective 10/1/2018
C43.122	Malignant melanoma of left lower eyelid, including canthus	Effective 10/1/2018
C43.20	Malignant melanoma of unspecified ear and external auricular canal	
C43.21	Malignant melanoma of right ear and external auricular canal	
C43.22	Malignant melanoma of left ear and external auricular canal	
C43.30	Malignant melanoma of unspecified part of face	
C43.31	Malignant melanoma of nose	
C43.39	Malignant melanoma of other parts of face	
C43.4	Malignant melanoma of scalp and neck	
C43.51	Malignant melanoma of anal skin	
C43.52	Malignant melanoma of skin of breast	
C43.59	Malignant melanoma of other part of trunk	
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	
C43.61	Malignant melanoma of right upper limb, including shoulder	
C43.62	Malignant melanoma of left upper limb, including shoulder	
C43.70	Malignant melanoma of unspecified lower limb, including hip	
C43.71	Malignant melanoma of right lower limb, including hip	
C43.72	Malignant melanoma of left lower limb, including hip	
C43.8	Malignant melanoma of overlapping sites of skin	
C43.9	Malignant melanoma of skin, unspecified	
C44.00	Unspecified malignant neoplasm of skin of lip	
C44.01	Basal cell carcinoma of skin of lip	
C44.02	Squamous cell carcinoma of skin of lip	
C44.09	Other specified malignant neoplasm of skin of lip	
C44.101	Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus	
C44.102	Unspecified malignant neoplasm of skin of right eyelid, including canthus	Expired 9/30/2018
C44.1021	Unspecified malignant neoplasm of skin of right upper eyelid, including canthus	Effective 10/1/2018
C44.1022	Unspecified malignant neoplasm of skin of right lower eyelid, including canthus	Effective 10/1/2018
C44.109	Unspecified malignant neoplasm of skin of left eyelid, including canthus	Expired 9/30/2018
C44.1091	Unspecified malignant neoplasm of skin of left upper eyelid, including canthus	Effective 10/1/2018

C44.1092	Unspecified malignant neoplasm of skin of left lower eyelid, including canthus	Effective 10/1/2018
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus	
C44.112	Basal cell carcinoma of skin of right eyelid, including canthus	Expired 9/30/2018
C44.1121	Basal cell carcinoma of skin of right upper eyelid, including canthus	Effective 10/1/2018
C44.1122	Basal cell carcinoma of skin of right lower eyelid, including canthus	Effective 10/1/2018
C44.119	Basal cell carcinoma of skin of left eyelid, including canthus	Expired 9/30/2018
C44.1191	Basal cell carcinoma of skin of left upper eyelid, including canthus	Effective 10/1/2018
C44.1192	Basal cell carcinoma of skin of left lower eyelid, including canthus	Effective 10/1/2018
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus	
C44.122	Squamous cell carcinoma of skin of right eyelid, including canthus	Expired 9/30/2018
C44.1221	Squamous cell carcinoma of skin of right upper eyelid, including canthus	Effective 10/1/2018
C44.1222	Squamous cell carcinoma of skin of right lower eyelid, including canthus	Effective 10/1/2018
C44.129	Squamous cell carcinoma of skin of left eyelid, including canthus	Expired 9/30/2018
C44.1291	Squamous cell carcinoma of skin of left upper eyelid, including canthus	Effective 10/1/2018
C44.1292	Squamous cell carcinoma of skin of left lower eyelid, including canthus	Effective 10/1/2018
C44.191	Other specified malignant neoplasm of skin of unspecified eyelid, including canthus	
C44.192	Other specified malignant neoplasm of skin of right eyelid, including canthus	Expired 9/30/2018
C44.1921	Other specified malignant neoplasm of skin of right upper eyelid, including canthus	Effective 10/1/2018
C44.1922	Other specified malignant neoplasm of skin of right lower eyelid, including canthus	Effective 10/1/2018
C44.199	Other specified malignant neoplasm of skin of left eyelid, including canthus	Expired 9/30/2018
C44.1991	Other specified malignant neoplasm of skin of left upper eyelid, including canthus	Effective 10/1/2018
C44.1992	Other specified malignant neoplasm of skin of left lower eyelid, including canthus	Effective 10/1/2018
C44.201	Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal	
C44.202	Unspecified malignant neoplasm of skin of right ear and external auricular canal	
C44.209	Unspecified malignant neoplasm of skin of left ear and external auricular canal	
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal	
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal	
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal	
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal	
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal	
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal	
C44.291	Other specified malignant neoplasm of skin of unspecified ear and external auricular canal	
C44.292	Other specified malignant neoplasm of skin of right ear and external auricular canal	
C44.299	Other specified malignant neoplasm of skin of left ear and external auricular canal	
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face	
C44.301	Unspecified malignant neoplasm of skin of nose	
C44.309	Unspecified malignant neoplasm of skin of other parts of face	
C44.310	Basal cell carcinoma of skin of unspecified parts of face	
C44.311	Basal cell carcinoma of skin of nose	
C44.319	Basal cell carcinoma of skin of other parts of face	
C44.320	Squamous cell carcinoma of skin of unspecified parts of face	
C44.321	Squamous cell carcinoma of skin of nose	
C44.329	Squamous cell carcinoma of skin of other parts of face	
C44.390	Other specified malignant neoplasm of skin of unspecified parts of face	
C44.391	Other specified malignant neoplasm of skin of nose	
C44.399	Other specified malignant neoplasm of skin of other parts of face	
C44.40	Unspecified malignant neoplasm of skin of scalp and neck	
C44.41	Basal cell carcinoma of skin of scalp and neck	
C44.42	Squamous cell carcinoma of skin of scalp and neck	
C44.49	Other specified malignant neoplasm of skin of scalp and neck	
C44.500	Unspecified malignant neoplasm of anal skin	
C44.501	Unspecified malignant neoplasm of skin of breast	
C44.509	Unspecified malignant neoplasm of skin of other part of trunk	
C44.510	Basal cell carcinoma of anal skin	
C44.511	Basal cell carcinoma of skin of breast	
C44.519	Basal cell carcinoma of skin of other part of trunk	
C44.520	Squamous cell carcinoma of anal skin	

C44.521 Squamous cell carcinoma of skin of breast  
C44.529 Squamous cell carcinoma of skin of other part of trunk  
C44.590 Other specified malignant neoplasm of anal skin  
C44.591 Other specified malignant neoplasm of skin of breast  
C44.599 Other specified malignant neoplasm of skin of other part of trunk  
C44.601 Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder  
C44.602 Unspecified malignant neoplasm of skin of right upper limb, including shoulder  
C44.609 Unspecified malignant neoplasm of skin of left upper limb, including shoulder  
C44.611 Basal cell carcinoma of skin of unspecified upper limb, including shoulder  
C44.612 Basal cell carcinoma of skin of right upper limb, including shoulder  
C44.619 Basal cell carcinoma of skin of left upper limb, including shoulder  
C44.621 Squamous cell carcinoma of skin of unspecified upper limb, including shoulder  
C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder  
C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder  
C44.691 Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder  
C44.692 Other specified malignant neoplasm of skin of right upper limb, including shoulder  
C44.699 Other specified malignant neoplasm of skin of left upper limb, including shoulder  
C44.701 Unspecified malignant neoplasm of skin of unspecified lower limb, including hip  
C44.702 Unspecified malignant neoplasm of skin of right lower limb, including hip  
C44.709 Unspecified malignant neoplasm of skin of left lower limb, including hip  
C44.711 Basal cell carcinoma of skin of unspecified lower limb, including hip  
C44.712 Basal cell carcinoma of skin of right lower limb, including hip  
C44.719 Basal cell carcinoma of skin of left lower limb, including hip  
C44.721 Squamous cell carcinoma of skin of unspecified lower limb, including hip  
C44.722 Squamous cell carcinoma of skin of right lower limb, including hip  
C44.729 Squamous cell carcinoma of skin of left lower limb, including hip  
C44.791 Other specified malignant neoplasm of skin of unspecified lower limb, including hip  
C44.792 Other specified malignant neoplasm of skin of right lower limb, including hip  
C44.799 Other specified malignant neoplasm of skin of left lower limb, including hip  
C44.80 Unspecified malignant neoplasm of overlapping sites of skin  
C44.81 Basal cell carcinoma of overlapping sites of skin  
C44.82 Squamous cell carcinoma of overlapping sites of skin  
C44.89 Other specified malignant neoplasm of overlapping sites of skin  
C44.90 Unspecified malignant neoplasm of skin, unspecified  
C44.91 Basal cell carcinoma of skin, unspecified  
C44.92 Squamous cell carcinoma of skin, unspecified  
C44.99 Other specified malignant neoplasm of skin, unspecified  
C45.0 Mesothelioma of pleura  
C45.1 Mesothelioma of peritoneum  
C45.2 Mesothelioma of pericardium  
C45.7 Mesothelioma of other sites  
C45.9 Mesothelioma, unspecified  
C47.0 Malignant neoplasm of peripheral nerves of head, face and neck  
C47.10 Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder  
C47.11 Malignant neoplasm of peripheral nerves of right upper limb, including shoulder  
C47.12 Malignant neoplasm of peripheral nerves of left upper limb, including shoulder  
C47.20 Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip  
C47.21 Malignant neoplasm of peripheral nerves of right lower limb, including hip  
C47.22 Malignant neoplasm of peripheral nerves of left lower limb, including hip  
C47.3 Malignant neoplasm of peripheral nerves of thorax  
C47.4 Malignant neoplasm of peripheral nerves of abdomen  
C47.5 Malignant neoplasm of peripheral nerves of pelvis  
C47.6 Malignant neoplasm of peripheral nerves of trunk, unspecified  
C47.8 Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system  
C47.9 Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified  
C48.0 Malignant neoplasm of retroperitoneum  
C48.1 Malignant neoplasm of specified parts of peritoneum



C48.2	Malignant neoplasm of peritoneum, unspecified	
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	
C49.3	Malignant neoplasm of connective and soft tissue of thorax	
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	
C49.A0	Gastrointestinal stromal tumor, unspecified site	
C49.A1	Gastrointestinal stromal tumor of esophagus	
C49.A2	Gastrointestinal stromal tumor of stomach	
C49.A3	Gastrointestinal stromal tumor of small intestine	
C49.A4	Gastrointestinal stromal tumor of large intestine	
C49.A5	Gastrointestinal stromal tumor of rectum	
C49.A9	Gastrointestinal stromal tumor of other sites	
C4A.0	Merkel cell carcinoma of lip	
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Expired 9/30/2018
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Effective 10/1/2018
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Effective 10/1/2018
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Expired 9/30/2018
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Effective 10/1/2018
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Effective 10/1/2018
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	
C4A.30	Merkel cell carcinoma of unspecified part of face	
C4A.31	Merkel cell carcinoma of nose	
C4A.39	Merkel cell carcinoma of other parts of face	
C4A.4	Merkel cell carcinoma of scalp and neck	
C4A.51	Merkel cell carcinoma of anal skin	
C4A.52	Merkel cell carcinoma of skin of breast	
C4A.59	Merkel cell carcinoma of other part of trunk	
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	
C4A.71	Merkel cell carcinoma of right lower limb, including hip	
C4A.72	Merkel cell carcinoma of left lower limb, including hip	
C4A.8	Merkel cell carcinoma of overlapping sites	
C4A.9	Merkel cell carcinoma, unspecified	
C50.011	Malignant neoplasm of nipple and areola, right female breast	
C50.012	Malignant neoplasm of nipple and areola, left female breast	
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	
C50.021	Malignant neoplasm of nipple and areola, right male breast	
C50.022	Malignant neoplasm of nipple and areola, left male breast	
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	
C50.111	Malignant neoplasm of central portion of right female breast	
C50.112	Malignant neoplasm of central portion of left female breast	
C50.119	Malignant neoplasm of central portion of unspecified female breast	

C50.121 Malignant neoplasm of central portion of right male breast  
C50.122 Malignant neoplasm of central portion of left male breast  
C50.129 Malignant neoplasm of central portion of unspecified male breast  
C50.211 Malignant neoplasm of upper-inner quadrant of right female breast  
C50.212 Malignant neoplasm of upper-inner quadrant of left female breast  
C50.219 Malignant neoplasm of upper-inner quadrant of unspecified female breast  
C50.221 Malignant neoplasm of upper-inner quadrant of right male breast  
C50.222 Malignant neoplasm of upper-inner quadrant of left male breast  
C50.229 Malignant neoplasm of upper-inner quadrant of unspecified male breast  
C50.311 Malignant neoplasm of lower-inner quadrant of right female breast  
C50.312 Malignant neoplasm of lower-inner quadrant of left female breast  
C50.319 Malignant neoplasm of lower-inner quadrant of unspecified female breast  
C50.321 Malignant neoplasm of lower-inner quadrant of right male breast  
C50.322 Malignant neoplasm of lower-inner quadrant of left male breast  
C50.329 Malignant neoplasm of lower-inner quadrant of unspecified male breast  
C50.411 Malignant neoplasm of upper-outer quadrant of right female breast  
C50.412 Malignant neoplasm of upper-outer quadrant of left female breast  
C50.419 Malignant neoplasm of upper-outer quadrant of unspecified female breast  
C50.421 Malignant neoplasm of upper-outer quadrant of right male breast  
C50.422 Malignant neoplasm of upper-outer quadrant of left male breast  
C50.429 Malignant neoplasm of upper-outer quadrant of unspecified male breast  
C50.511 Malignant neoplasm of lower-outer quadrant of right female breast  
C50.512 Malignant neoplasm of lower-outer quadrant of left female breast  
C50.519 Malignant neoplasm of lower-outer quadrant of unspecified female breast  
C50.521 Malignant neoplasm of lower-outer quadrant of right male breast  
C50.522 Malignant neoplasm of lower-outer quadrant of left male breast  
C50.529 Malignant neoplasm of lower-outer quadrant of unspecified male breast  
C50.611 Malignant neoplasm of axillary tail of right female breast  
C50.612 Malignant neoplasm of axillary tail of left female breast  
C50.619 Malignant neoplasm of axillary tail of unspecified female breast  
C50.621 Malignant neoplasm of axillary tail of right male breast  
C50.622 Malignant neoplasm of axillary tail of left male breast  
C50.629 Malignant neoplasm of axillary tail of unspecified male breast  
C50.811 Malignant neoplasm of overlapping sites of right female breast  
C50.812 Malignant neoplasm of overlapping sites of left female breast  
C50.819 Malignant neoplasm of overlapping sites of unspecified female breast  
C50.821 Malignant neoplasm of overlapping sites of right male breast  
C50.822 Malignant neoplasm of overlapping sites of left male breast  
C50.829 Malignant neoplasm of overlapping sites of unspecified male breast  
C50.911 Malignant neoplasm of unspecified site of right female breast  
C50.912 Malignant neoplasm of unspecified site of left female breast  
C50.919 Malignant neoplasm of unspecified site of unspecified female breast  
C50.921 Malignant neoplasm of unspecified site of right male breast  
C50.922 Malignant neoplasm of unspecified site of left male breast  
C50.929 Malignant neoplasm of unspecified site of unspecified male breast  
C51.0 Malignant neoplasm of labium majus  
C51.1 Malignant neoplasm of labium minus  
C51.2 Malignant neoplasm of clitoris  
C51.8 Malignant neoplasm of overlapping sites of vulva  
C51.9 Malignant neoplasm of vulva, unspecified  
C52 Malignant neoplasm of vagina  
C53.0 Malignant neoplasm of endocervix  
C53.1 Malignant neoplasm of exocervix  
C53.8 Malignant neoplasm of overlapping sites of cervix uteri  
C53.9 Malignant neoplasm of cervix uteri, unspecified  
C54.0 Malignant neoplasm of isthmus uteri  
C54.1 Malignant neoplasm of endometrium

C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C57.9	Malignant neoplasm of female genital organ, unspecified
C58	Malignant neoplasm of placenta
C60.0	Malignant neoplasm of prepuce
C60.1	Malignant neoplasm of glans penis
C60.2	Malignant neoplasm of body of penis
C60.8	Malignant neoplasm of overlapping sites of penis
C60.9	Malignant neoplasm of penis, unspecified
C61	Malignant neoplasm of prostate
C62.00	Malignant neoplasm of unspecified undescended testis
C62.01	Malignant neoplasm of undescended right testis
C62.02	Malignant neoplasm of undescended left testis
C62.10	Malignant neoplasm of unspecified descended testis
C62.11	Malignant neoplasm of descended right testis
C62.12	Malignant neoplasm of descended left testis
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended
C63.00	Malignant neoplasm of unspecified epididymis
C63.01	Malignant neoplasm of right epididymis
C63.02	Malignant neoplasm of left epididymis
C63.10	Malignant neoplasm of unspecified spermatic cord
C63.11	Malignant neoplasm of right spermatic cord
C63.12	Malignant neoplasm of left spermatic cord
C63.2	Malignant neoplasm of scrotum
C63.7	Malignant neoplasm of other specified male genital organs
C63.8	Malignant neoplasm of overlapping sites of male genital organs
C63.9	Malignant neoplasm of male genital organ, unspecified
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter

C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68.0	Malignant neoplasm of urethra
C68.1	Malignant neoplasm of paraurethral glands
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C68.9	Malignant neoplasm of urinary organ, unspecified
C69.00	Malignant neoplasm of unspecified conjunctiva
C69.01	Malignant neoplasm of right conjunctiva
C69.02	Malignant neoplasm of left conjunctiva
C69.10	Malignant neoplasm of unspecified cornea
C69.11	Malignant neoplasm of right cornea
C69.12	Malignant neoplasm of left cornea
C69.20	Malignant neoplasm of unspecified retina
C69.21	Malignant neoplasm of right retina
C69.22	Malignant neoplasm of left retina
C69.30	Malignant neoplasm of unspecified choroid
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid
C69.40	Malignant neoplasm of unspecified ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.42	Malignant neoplasm of left ciliary body
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct
C69.51	Malignant neoplasm of right lacrimal gland and duct
C69.52	Malignant neoplasm of left lacrimal gland and duct
C69.60	Malignant neoplasm of unspecified orbit
C69.61	Malignant neoplasm of right orbit
C69.62	Malignant neoplasm of left orbit
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa
C69.90	Malignant neoplasm of unspecified site of unspecified eye
C69.91	Malignant neoplasm of unspecified site of right eye
C69.92	Malignant neoplasm of unspecified site of left eye
C70.0	Malignant neoplasm of cerebral meninges
C70.1	Malignant neoplasm of spinal meninges
C70.9	Malignant neoplasm of meninges, unspecified
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72.0	Malignant neoplasm of spinal cord
C72.1	Malignant neoplasm of cauda equina
C72.20	Malignant neoplasm of unspecified olfactory nerve

C72.21	Malignant neoplasm of right olfactory nerve
C72.22	Malignant neoplasm of left olfactory nerve
C72.30	Malignant neoplasm of unspecified optic nerve
C72.31	Malignant neoplasm of right optic nerve
C72.32	Malignant neoplasm of left optic nerve
C72.40	Malignant neoplasm of unspecified acoustic nerve
C72.41	Malignant neoplasm of right acoustic nerve
C72.42	Malignant neoplasm of left acoustic nerve
C72.50	Malignant neoplasm of unspecified cranial nerve
C72.59	Malignant neoplasm of other cranial nerves
C72.9	Malignant neoplasm of central nervous system, unspecified
C73	Malignant neoplasm of thyroid gland
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland
C74.01	Malignant neoplasm of cortex of right adrenal gland
C74.02	Malignant neoplasm of cortex of left adrenal gland
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland
C74.11	Malignant neoplasm of medulla of right adrenal gland
C74.12	Malignant neoplasm of medulla of left adrenal gland
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91	Malignant neoplasm of unspecified part of right adrenal gland
C74.92	Malignant neoplasm of unspecified part of left adrenal gland
C75.0	Malignant neoplasm of parathyroid gland
C75.1	Malignant neoplasm of pituitary gland
C75.2	Malignant neoplasm of craniopharyngeal duct
C75.3	Malignant neoplasm of pineal gland
C75.4	Malignant neoplasm of carotid body
C75.5	Malignant neoplasm of aortic body and other paraganglia
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified
C75.9	Malignant neoplasm of endocrine gland, unspecified
C76.0	Malignant neoplasm of head, face and neck
C76.1	Malignant neoplasm of thorax
C76.2	Malignant neoplasm of abdomen
C76.3	Malignant neoplasm of pelvis
C76.40	Malignant neoplasm of unspecified upper limb
C76.41	Malignant neoplasm of right upper limb
C76.42	Malignant neoplasm of left upper limb
C76.50	Malignant neoplasm of unspecified lower limb
C76.51	Malignant neoplasm of right lower limb
C76.52	Malignant neoplasm of left lower limb
C76.8	Malignant neoplasm of other specified ill-defined sites
C7A.00	Malignant carcinoid tumor of unspecified site
C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.023	Malignant carcinoid tumor of the transverse colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.090	Malignant carcinoid tumor of the bronchus and lung
C7A.091	Malignant carcinoid tumor of the thymus
C7A.092	Malignant carcinoid tumor of the stomach
C7A.093	Malignant carcinoid tumor of the kidney

C7A.094	Malignant carcinoid tumor of the foregut, unspecified
C7A.095	Malignant carcinoid tumor of the midgut, unspecified
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified
C7A.098	Malignant carcinoid tumors of other sites
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7A.8	Other malignant neuroendocrine tumors
C80.0	Disseminated malignant neoplasm, unspecified
C80.1	Malignant (primary) neoplasm, unspecified
C80.2	Malignant neoplasm associated with transplanted organ

**ICD-10-CM****ICD-10-CM Code Descriptor****Effective Date: 03/16/2018**

C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung